CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- 4 Open-market sale Chief Executive Officer sold 8,301 shares at an average $230.99 ($1,917,475)
- 4 Open-market sale EVP, Chief Financial Officer sold 1,605 shares at an average $231.00 ($370,747)
- 4 Open-market sale EVP, Chief Commercial Officer sold 1,605 shares at an average $231.00 ($370,747)
- 4 Open-market sale CSO & EVP, Head of Research sold 1,198 shares at an average $230.99 ($276,731)
- 4 Planned sale Director sold 21,700 shares at an average $148.60 ($3,224,546)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award EVP, Chief Commercial Officer acquired 4,751 shares (grant or award)
- 4 Grant or award CMO & EVP Dev & Med Affairs acquired 4,751 shares (grant or award)
- 4 Grant or award EVP, Chief Financial Officer acquired 7,741 shares (grant or award)
Page 7 of 47 · 936 filings